Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.032,03+0,41 %

Gold3.298,30-0,50 %

Öl (Brent)64,30-0,47 %

Dow Jones41.940,55+0,16 %

US Tech 10021.181,96+0,40 %

EUR/USD1,12613-0,62 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Aktie

ISIN: US92536C1036 WKN: A2DV3C SYM: FMW Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,4344

EUR

-3,72 %

-0,0168 EUR

Letzter Kurs 21.05.25 Tradegate

Veru Aktie kaufen

Geldkurs

19:18:33

0,4272

EUR

9.400 STK

Briefkurs

19:18:33

0,4462

EUR

9.000 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level 08.05.25 · Accesswire · Nasdaq Inc. Aktie
Veru Participates in a Virtual Investor KOL Connect Segment 08.05.25 · globenewswire · Veru
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress 08.05.25 · globenewswire · Veru
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 01.05.25 · globenewswire · Veru
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit 16.04.25 · globenewswire · Veru
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference 31.03.25 · globenewswire · Veru
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress 13.02.25 · globenewswire · Veru
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025 06.02.25 · globenewswire · Veru
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference 04.02.25 · globenewswire · Veru
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction 27.01.25 · globenewswire · Veru
Veru Announces the Sale of the FC2 Female Condom (Internal Condom) Business 31.12.24 · globenewswire · Veru
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders 26.11.24 · globenewswire · Veru

1
2

Meistgelesen

30 Tage
12 Monate

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 152 Leser
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) ... 132 Leser
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress 124 Leser
Veru Participates in a Virtual Investor KOL Connect Segment 120 Leser

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and ... 992 Leser
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction 736 Leser
Veru Announces the Sale of the FC2 Female Condom (Internal Condom) Business 396 Leser
Veru to Present at the 2024 Cantor Global Healthcare Conference 364 Leser
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism 252 Leser
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress 236 Leser
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference 216 Leser
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American ... 208 Leser
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025 208 Leser
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which ... 204 Leser